Mehdi Khamaily*, Imane Tarib, Yassine Mouzari, Joumany Brahim Salem, Taoufik Abdellaoui, Fouad El Asri, Karim Reda, Abdelbarre Oubaaz
Purpose: To describe our clinical experience with the efficacy and safety of micropulse transscleralcyclophoto
coagulation as a alternative treatment for refractory glaucoma.
Methods: It is a prospective, non-comparative, longitudinal interventional study conducted on 26 eyes, which
presented refractory glaucoma, treated and followed at the Mohammed V Military Teaching Hospital, for a period of
one year, between January 2019 and January 2020.
Eligible patients underwent a standardized cyclophoto coagulation treatment with micropulsed diode laser by placing
the probe 1 mm from the limbus, for 90 seconds over 360 º while sparing the meridians of 3h and 9h to avoid the
branches of the anterior ciliary artery and the posterior ciliary nerves, we used a power of 2000mw, a cycle of 35 ms.
Results: We included 18 men and 8 women in our study, the average age is 62.78 ± 6.33 years, 19 patients who were
under an average of 3.21 ± 1.33 treatment molecules.
19 patients were on 4 or more treatment molecules and the visual acuity was between negative light perception and
3/10.The average IOP at 6 weeks postoperatively decreased with an average of 17.31 ± 4.91 mmHg which is a decrease
of 56.08% .The decrease in IOP at 6 weeks as well as the number of therapies per patient experienced a significant
drop with a p value <0.001 in comparison with the preoperative values.
Conclusion: The transcleral Micropulsecyclo coagulation proved good results in the management of refractory
glaucoma, in comparison to the Nd: YAG laser technique. Certainly, further follow up for long-term results is
essential.